2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Breast Neoplasms
4
Leukemia, Myeloid, Acute
3
Colorectal Neoplasms
3
Lymphoma, Non-Hodgkin
2
Carcinoma, Basal Cell
2
Breast Diseases
2
Basal Cell Nevus Syndrome
2
Upper Tract Urothelial Carcinomas
1
Thrombocythemia, Essential
1
Solid Tumors
1
Serous Ovarian Cancer
1
Recurrence
1
Postmenopausal Women With ER+ HER2- Primary Breast Cancer
1
Polycythemia Vera
1
Ovarian Neoplasms
1
Lymphedema
1
Liver Neoplasms
1
Leukemia
1
Immunoglobulin Light-chain Amyloidosis
1
Hypogonadism
1
Glioma
1
Gastric Adenocarcinoma
1
Fatigue Syndrome, Chronic
1
Eunuchism
1
Colonic Neoplasms
1
Amyloidosis
1
Adenoma
1
Interventions
fludarabine phosphate
29
ruxolitinib
28
Peripheral Blood Stem Cell Transplantation
26
Cyclophosphamide
25
Busulfan
21
Tacrolimus
16
Whole-Body Irradiation
15
Mycophenolic Acid
14
Methotrexate
13
Cyclosporine
12
Hydroxyurea
11
Antilymphocyte Serum
11
Aspirin
9
fludarabine
8
Filgrastim
8
Melphalan
7
Etoposide
7
Decitabine
7
peginterferon alfa-2a
6
Imatinib Mesylate
6
Cytarabine
6
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
6
givinostat hydrochloride
5
givinostat
5
Radiotherapy
5
Prednisone
5
Carboplatin
5
Biopsy
5
Topotecan
4
Thiotepa
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Polycythemia Vera
×
Drug Evaluation
×
Clear all
NCT02577926
2025-06-10
Ruxo-BEAT
RWTH Aachen University
Phase 2
Active not recruiting
207 enrolled